Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.

AIM: To perform an indirect treatment comparison of safety outcomes between the Janus kinase (JAK) inhibitors momelotinib and fedratinib in patients with myelofibrosis.

METHODS

Adverse events (AEs) for JAK inhibitor - naive and - experienced populations occurring in ≥ 10% of patients treated with momelotinib (SIMPLIFY-1/SIMPLIFY-2/MOMENTUM) or fedratinib (JAKARTA/JAKARTA-2) in phase 2/3 trials were evaluated using matching-adjusted indirect comparisons.

RESULTS

Risk of any-grade or grade 3/4 anemia, diarrhea, nausea, and treatment-emergent AEs leading to dose reductions was lower with momelotinib in both populations; any-grade thrombocytopenia was also significantly less likely in JAK inhibitor - naive patients.

CONCLUSIONS

Momelotinib showed a favorable safety profile vs fedratinib, including significantly lower risks of key hematologic and gastrointestinal AEs - such as anemia, diarrhea, and nausea - over 24 weeks.